gdc
Gastric Cancer

Drugs for Gastric/Gastroesophageal Junction Cancer

Here are the financial support services available to patients receiving treatment for Gastric/Gastroesophageal Junction Cancer.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used as a single drug, or in combination with Taxol, for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that progressed after chemotherapy.

Lilly PatientOne offers 2 financial assistance programs for patients using Cyramza:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and a household income up to 500% or less of the federal poverty level, this program provides Cyramza at no cost.

Herceptin (trastuzumab)

Drug company: Genentech
866-422-2377

Herceptin is a HER2 receptor antagonist used for the treatment of patients with HER2-overexpressing, metastatic gastric or gastroesophageal junction adenocarcinoma.

Genentech Access Solutions offers 2 financial assistance programs for patients using Herceptin:

Genentech BioOncology Co-pay Card

This program ensures a $25 copay for patients with private insurance, with up to $25,000 of the drug cost paid by this program annually. This program has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Herceptin free of charge to uninsured and underinsured patients whose household income is less than $100,000. Herceptin is also provided free of charge to patients whose household income is less than $150,000 and their out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that is expressing PD-L1, as determined by an FDA-approved test, and is progressing during or after ≥2 lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy, and when appropriate, HER2-targeted therapy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $60,300 or less for individuals, $81,200 or less for a couple, or $123,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Table. Drugs Prescribed for Gastric/Gastroesophageal Junction Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that is expressing PD-L1 and is progressing during or after ≥2 lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy, and when appropriate, HER2-targeted therapy
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932

Last modified: July 10, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country